Table 3.
Adverse events (safety population).
| Variable | Xacrel (N = 85) |
Ocrevus (N = 85) |
|---|---|---|
| Number of patients (%) | ||
| Any adverse event | 83 (97.65) | 83 (97.65) |
| Infusion-related reaction | 51 (60) | 54 (63.53) |
| Infections and infestations | ||
| Herpes zoster | 1 (1.2) | 1 (1.2) |
| Oral herpes | 1 (1.2) | 3 (3.5) |
| Genital herpes | 0 (0) | 1 (1.2) |
| Urinary tract infection | 4 (4.7) | 1 (1.2) |
| Corona virus infection | 21 (24.7) | 25 (29.4) |
| Neoplasms benign, malignant and unspecified | 1 (1.2) | 1 (1.2) |
| Any serious adverse event | 8 (9.41) | 12 (14.12) |
| Serious infections and infestations | 5 (5.90) | 8 (9.41) |